CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Loading
Home
News
Healthleap raises $38M for its AI that flags hospital patients who may need a closer look

From TechCrunch

By Ram Iyer

October 7, 2026

Healthleap raises $38M for its AI that flags hospital patients who may need a closer look

Healthleap raises $38M for its AI that flags hospital patients who may need a closer look

Healthleap, a startup building an AI platform that reads patient records to identify patients at risk of undiagnosed illnesses, has raised $38 million in seed and Series A funding, TechCrunch has exclusively learned.

The financing includes an $8 million seed round co-led by Sequoia Capital and First Round Capital, and a $30 million Series A led by Hummingbird Ventures. The company is not disclosing its valuation.

Founded in South Africa in 2022 by siblings Jemima and Josiah Meyer (pictured above), the startup initially offered a clinical nutrition tool Jemima had built for dietitians. But the company later pivoted and built a more general-purpose platform that aims to identify patients admitted to hospitals who may be suffering from conditions like malnutrition or delirium that aren’t often identified early enough, CEO and co-founder Josiah Meyer told TechCrunch.

“A patient’s chart holds two kinds of data. Labs, weights, and vital signs sit in structured fields, but the most telling signs sit in clinicians’ written notes: poor appetite, recent weight loss, muscle loss, trouble swallowing. Our developing approach is extracting affirmative or negated mentions of these clinical concepts in an easily extensible and scalable way,” Josiah said.

The company’s platform is currently deployed in more than 50 hospitals, where it screens patients for conditions such as malnutrition and delirium, he said. The startup has also built programs to identify aspiration pneumonia, pressure ulcers, and risk of readmission for congestive heart failure, which Josiah said are undergoing further clinical validation.

To find patients that may be at risk of an illness or were undiagnosed, Healthleap plugs into a hospital’s electronic health record system and uses language models to pull information from written notes, such as references to recent weight loss or difficulty swallowing. That analysis is then fed into its risk models, alongside structured information such as lab reports and vitals to surface patients who may need a closer look. The company notes that its software doesn’t diagnose patients, only highlights items for additional review.

“Each night, we analyze every adult inpatient’s record: lab results, vital signs, weights, medications, diet orders, diagnoses, clinicians’ notes, and more,” Josiah explained. “Each morning, we write a risk score into the care team’s existing workflow with a dashboard accessible that holds additional information about the patients’ trends.”

Malnutrition likely served as a useful starting point for Healthleap, as it’s a condition that often goes undiagnosed and can adversely impact patient recovery in a variety of ways. Research suggests 20% to 50% of hospital inpatients are malnourished, and some studies have linked malnutrition with longer stays, impaired wound healing, infections and other complications, as well as higher morbidity and mortality.

Josiah said Healthleap has grown from three hospital partners to more than 50 over the past year, and its customers now include Penn Medicine, Cedars-Sinai, Intermountain, Houston Methodist and Emory Healthcare. Revenue has grown more than 10x over the same period, he said, though he didn’t disclose specifics.

The startup sells three-year contracts priced according to a hospital’s licensed bed count, and also uses an outcome-based pricing model. “We use the hard ROI that the hospital finance team validates and attributes to us as the measurable ROI. Based on that, we contractually ensure that we deliver multiples of the contract price. To date, every customer has seen a 5x hard ROI or more, in some cases over 20x annual total ROI,” Josiah said.

At the Hospital of the University of Pennsylvania, Healthleap says its malnutrition program resulted in $23.8 million in annualized financial impact, of which $6.3 million came from additional reimbursement and $17.5 million from shorter hospital stays.

Healthleap plans to spend the fresh cash on engineering, product, sales, and customer success as it adds support for identifying more conditions. Meyer said the company ultimately wants to cover more than 40 major health conditions and expand into outpatient and home care.

View original article on techcrunch.com

Most Recent

Ex-Trump AI Adviser Sriram Krishnan Targets Raising a $500 Million Venture Fund

Sriram Krishnan, a key AI adviser to President Donald Trump who left the White House in June, is raising an AI-focused venture fund …

Oct 7, 2026

GPT-6 and Intelligent UI for everyone

GPT‑6 is rolling out globally in ChatGPT with Intelligent UI, delivering faster responses with visuals and interactive experiences you can explore and use directly.

Oct 7, 2026

Surface RTX Spark Dev Box is available for preorder for $5,999

Microsoft's high-end AI mini PC for developers starts shipping in November. — Microsoft's Nvidia-powered Surface RTX Spark Dev Box …

Oct 7, 2026

Meta rolls out new AI tools to detect ads that secretly lead to child sexual abuse material

Meta launches new AI tools after discovering ads on its platforms that may look normal but direct users to harmful content elsewhere online.

Oct 7, 2026

Similar Posts

Reco raises $55M as AI agent security startups crowd the market

The round builds on a $30 million fundraise in February, taking the company's total funding to $140 million.

Sep 29, 2026

Profound raises $180M to boost brands’ visibility in AI services

Marketing technology startup Profound today announced that it has raised $180 million in funding at a $1.8 billion valuation. Sequoia Capital and Kleiner Perkins jointly led the Series D investment. They were joined by Lightspeed Venture Partners, Khosla Ventures, Saga Ventures, Evantic and South Pa

Sep 15, 2026

Optura Raises $17.5M to Expand Healthcare AI Platform

Nashville-based Optura raised $17.5 million in Series A funding to scale its ROAI platform for healthcare organizations.

May 14, 2026

Sequoia unveils $950M in new early-stage funds as it strives to be ‘only as good as our next investment’

The legendary firm launched a $750 million early-stage fund targeting Series A startups and a $200 million seed fund.

Oct 27, 2025